Lexaria Bioscience (LEXX) News Today → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free LEXX Stock Alerts $3.55 -0.05 (-1.39%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineLexaria Bioscience Corp. (NASDAQ:LEXX) Short Interest Updateamericanbankingnews.com - May 12 at 4:48 AMLexaria (NASDAQ: LEXX) Set to Extend Runway to 2025 Following Warrant Exercise, Issuancetheglobeandmail.com - May 10 at 12:47 PMLexaria Bioscience (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2theglobeandmail.com - May 9 at 9:44 PMLexaria (NASDAQ: LEXX) Targeting Massive Type 2 Diabetes and Obesity Markets with DehydraTECH(TM)theglobeandmail.com - May 8 at 5:08 PMLexaria Bioscience Corp.: Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Studyfinanznachrichten.de - May 8 at 9:49 AMLexaria (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 Drugstheglobeandmail.com - May 7 at 11:43 PMFY2024 Earnings Forecast for Lexaria Bioscience Corp. Issued By Zacks Small Cap (NASDAQ:LEXX)americanbankingnews.com - May 2 at 2:04 AMLexaria Bioscience Corp.: Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuancefinanznachrichten.de - April 30 at 6:03 PMLexaria Bioscience, BioSig Technologies, BIMI Holdings among healthcare moversmsn.com - April 17 at 12:49 PMLexaria Bioscience Corp.: Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Studyfinanznachrichten.de - April 16 at 11:09 AMLexaria Bioscience Corp LEXXmorningstar.com - April 5 at 11:50 PMLexaria (NASDAQ: LEXX) Marks 2024 Milestone with FDA Clearance for Planned U.S. Phase 1b Hypertension Trialtheglobeandmail.com - March 19 at 12:14 PMLexaria Bioscience Revolutionizes Drug Delivery with DehydraTECH for GLP-1 drugproactiveinvestors.com - March 18 at 4:12 PMLexaria Bioscience (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFOtheglobeandmail.com - March 15 at 9:26 PMLexaria Bioscience Corp.: Lexaria Appoints Nelson Cabatuan as Chief Financial Officerfinanznachrichten.de - March 14 at 10:51 AMLexaria Bioscience Corp.: Lexaria Awards Contract For Next GLP-1 Human Pilot Studyfinanznachrichten.de - March 7 at 1:25 PMLexaria to test DehydraTECH GLP-1 product for weight loss, diabetesmsn.com - March 5 at 1:07 PMLexaria Bioscience Corp.: 7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Studyfinanznachrichten.de - March 4 at 10:39 AM7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Studyfinance.yahoo.com - March 4 at 10:39 AMLexaria slips despite FDA nod to test blood pressure drugmsn.com - March 1 at 7:05 PMThis Lexaria Bioscience Insider Increased Their Holding By 23% Last Yearfinance.yahoo.com - February 18 at 12:37 PMLexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - February 16 at 6:40 PMLexaria Bioscience Corp.: Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinanznachrichten.de - February 15 at 8:40 AMLexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - February 15 at 8:40 AMLexaria Bioscience’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Improves Delivery of GLP-1 Drugtheglobeandmail.com - February 13 at 9:55 PMLexaria Bioscience (NASDAQ: LEXX) To Hit High Ground in Q2/Q3 2024 with Animal, Human GLP-1 Studiestheglobeandmail.com - January 30 at 1:59 PMLexaria's Submits Investigational New Drug Applicationfinance.yahoo.com - January 30 at 8:59 AMLEXX’ Sweet Opportunity in GLP-1sfinance.yahoo.com - January 22 at 11:03 AMLEXX Stock Earnings: Lexaria Bioscience Reported Results for Q1 2024investorplace.com - January 22 at 9:02 AMLexaria Bioscience Corp.: Lexaria Unveils Extensive Planned 2024 GLP-1 Study Programfinanznachrichten.de - January 16 at 12:00 PMLexaria (NASDAQ: LEXX) Looking to Grow Revenue, Commercial Opportunities Through Licensingtheglobeandmail.com - January 16 at 12:00 PMNetworkNewsWire: GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckonsfinanznachrichten.de - January 10 at 7:13 PMLexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platformfinance.yahoo.com - January 9 at 8:38 AMNetworkNewsWire: Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugsfinanznachrichten.de - January 8 at 9:49 AMLexaria Bioscience Corp.: Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus-Branded GLP-1 drug Semaglutidefinanznachrichten.de - January 4 at 1:53 PMLexaria Slides on New Drug Developmentsmsn.com - January 4 at 1:53 PMLexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutidefinance.yahoo.com - January 4 at 1:53 PMLexaria Bioscience Corp.: Lexaria's Investigational New Drug Application Filing Updatefinanznachrichten.de - December 7 at 10:08 AMLexaria's Investigational New Drug Application Filing Updatefinance.yahoo.com - December 7 at 10:08 AMLexaria Bioscience files to sell 1.62M for its holdersseekingalpha.com - December 1 at 8:54 AMLexaria (NASDAQ: LEXX) Tech Lowers Blood Glucose More Effectively than Semaglutide Alonetheglobeandmail.com - November 28 at 8:13 PMLexaria's Technology Improves the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide in Human Pilot Studybenzinga.com - November 28 at 3:13 PMLexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Studyfinance.yahoo.com - November 28 at 10:12 AMLexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugsfinance.yahoo.com - October 31 at 1:36 PMLexaria Bioscience Corp.: Lexaria Granted Two New Patents in Canadafinanznachrichten.de - October 12 at 12:42 PMLexaria Granted Two New Patents in Canadafinance.yahoo.com - October 12 at 12:42 PMLexaria Bioscience’s (NASDAQ: LEXX) DehydraTECH(TM)-Nicotine Pouch Demonstrates Advantages over Competitiontheglobeandmail.com - October 4 at 12:13 AMLexaria Bioscience enters into securities purchase agreementseekingalpha.com - October 1 at 7:54 PMLexaria Bioscience Corp.: Lexaria Announces Pricing of $1.6 Million Registered Direct Offeringfinanznachrichten.de - September 29 at 9:22 AMLexaria (NASDAQ: LEXX) to Demonstrate DehydraTECH-CBD Benefits in Upcoming IND Applicationtheglobeandmail.com - September 23 at 7:34 AM Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Email Address READ THIS – If You Missed Out On The AI Boom (Ad)Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.” Click on Adam's shiny forehead for more details. LEXX Media Mentions By Week LEXX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LEXX News Sentiment▼0.360.58▲Average Medical News Sentiment LEXX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LEXX Articles This Week▼81▲LEXX Articles Average Week Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NXTC News Today UNCY News Today CARA News Today SNSE News Today IMRX News Today XLO News Today EYEN News Today BOLT News Today VYNE News Today RMTI News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LEXX) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICShocking: One AI startup's revenue could surge 4,735%Manward PressMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlaceCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
